Executive summary

This MD Anderson study compared toxicity profiles and clinical outcomes after IMPT versus PSPT for 139 patients with locally advanced NSCLC. Compared to the PSPT group (n=86, 62%), the IMPT cohort (n=53, 38%) had lower rates of grade 3 or higher pulmonary (17% versus 2%, p = 0.005) and cardiac (11% versus 0%, p = 0.01) toxicities.

Six patients (7%) with PSPT and zero patients (0%) with IMPT experienced grade 4 or 5 toxicity. There was also a trend towards a longer median overall survival in the IMPT group (23.9 mo versus 36.2 mo, p = 0.09).

Top cancer treatments